Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S; Gynecologic Oncology Group.

J Clin Oncol. 2008 Sep 1;26(25):4144-50. doi: 10.1200/JCO.2007.13.1961.


Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.


Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.


Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.

Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group.

J Clin Oncol. 2007 Feb 1;25(4):437-43.


Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

Young M, Plosker GL.

Pharmacoeconomics. 2001;19(12):1227-59. Review.


The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.


At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.

Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr.

J Clin Oncol. 2011 Apr 1;29(10):1247-51. doi: 10.1200/JCO.2010.32.1075. Epub 2011 Mar 7.


Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.


Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS.

J Clin Oncol. 2003 Apr 1;21(7):1313-9.


Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.

Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA.

Cancer. 2012 Jan 15;118(2):386-91. doi: 10.1002/cncr.26199. Epub 2011 May 19.


Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.

Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.

Gynecol Oncol. 2010 Mar;116(3):340-4. doi: 10.1016/j.ygyno.2009.10.054. Epub 2009 Nov 17.


Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR.

Lung Cancer. 2013 Oct;82(1):121-7. doi: 10.1016/j.lungcan.2013.07.021. Epub 2013 Aug 7.


Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group.

N Engl J Med. 2006 Jan 5;354(1):34-43.


A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.


BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.


CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.

Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D, Thaler HT.

Gynecol Oncol. 2012 Feb;124(2):216-20. doi: 10.1016/j.ygyno.2011.10.021. Epub 2011 Oct 25.


From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Limat S, Woronoff-Lemsi MC, Menat C, Madroszyk-Flandin A, Merrouche Y.

Pharmacoeconomics. 2004;22(10):633-41.

Items per page

Supplemental Content

Write to the Help Desk